An Observational Study of the First Experience with Bevacizumab
for the Treatment of Patients with Recurrent High-Grade Glioma in
Two Belgian University Hospitals
Table 1
Patient baseline characteristics.
Variable
No. of patients
%
Treated population
19
100
Age of treated population
Median (range)
40 (28 to 70)
Sex of treated population
Male/female
11/8
58/42
Tumor location
Frontal
9
47
Temporal
5
26
Parietal
3
16
Occipital
1
5
Thalamus
1
5
Initial tumor histology
Astrocytoma
1
5
Anaplastic astrocytoma
3
16
Anaplastic oligodendroglioma
1
5
Anaplastic oligoastrocytoma
5
26
Glioblastoma
9
47
Latest tumor histology
Anaplastic astrocytoma
2
10
Anaplastic oligodendroglioma
0
0
Anaplastic oligoastrocytoma
3
16
Glioblastoma
14
74
Surgery at primary diagnosis
18
95
Total resection
6*
32
Subtotal resection
7
37
Biopsy
3*
16
Unknown extent
3
16
Radiotherapy at primary diagnosis
19
100
Concurrent temozolomide
15
79
Adjuvant temozolomide
13
68
Surgery for relapse
10
53
Radiotherapy for relapse
3
16
Fractionated
1
5
γ-knife
2
11
Temozolomide for relapse
7
37
Salvage therapy prior to BEV therapy°
12
63
CCNU
3
16
Dendritic cell vaccine
4
21
PCV
2
11
REGAL study: CCNU+cediranib/placebo
5
26
Sutent study: Sunitinib/CCNU
3
16
*One patient had a biopsy, followed by gross tumor resection.
°Seven patients had one salvage therapy prior to BEV therapy. Five patients had the salvage therapies prior to BEV therapy.
